Hudson Bay Capital Management
CYTK icon

Hudson Bay Capital Management’s Cytokinetics CYTK Stock Holding History

Hudson Bay Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-161,000
Closed -$10.6M – 1422
2026
Q1 		$10.6M Buy
+161,000
New +$10.2M 0.04% 303

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hudson Bay Capital Management's CYTK Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Cytokinetics (CYTK) stake by 24% in Q2 2026, selling an estimated $680K and leaving 30,000 shares worth $2.56M. The position accounts for 0.01% of the portfolio, ranked #756.

Hudson Bay Capital Management first reported a position in CYTK in Q4 2019 and has held it in 15 quarters since. The position peaked at $17.4M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Hudson Bay Capital Management held 30,000 shares of Cytokinetics worth $2.56M as of Q2 2026.
  • Hudson Bay Capital Management sold 9,470 Cytokinetics shares in Q2 2026, an estimated $680K.
  • Cytokinetics made up 0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #756 holding.
  • Hudson Bay Capital Management first reported a position in Cytokinetics in Q4 2019 and has held it in 15 quarters since.
  • Hudson Bay Capital Management's Cytokinetics position peaked at $17.4M in Q1 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.